1. Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice
- Author
-
Todd M. Morgan, Javed Siddiqui, Rana Kabeer, Arul M. Chinnaiyan, Jeffrey J. Tosoian, Zoey Chopra, Rabia Siddiqui, Matthew S. Davenport, Nicholas W. Eyrich, Scott A. Tomlins, Yashar S. Niknafs, John T. Wei, Rohit Mehra, Lakshimi P. Kunju, Christopher M. Russell, Amir H. Lebastchi, Takahiro Osawa, and Rachel Botbyl
- Subjects
Male ,medicine.medical_specialty ,Prostate biopsy ,Referral ,Biopsy ,Urology ,Clinical Decision-Making ,Population ,030232 urology & nephrology ,Academic practice ,Logistic regression ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Antigens, Neoplasm ,Internal medicine ,Clinical endpoint ,Humans ,Medicine ,Prostate Cancer Prevention Trial ,Multiparametric Magnetic Resonance Imaging ,education ,Clinical decision ,Aged ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Prostate ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,3. Good health ,Test (assessment) ,030220 oncology & carcinogenesis ,Cohort ,Radiology ,business - Abstract
ObjectiveTo evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy at a contemporary academic urology practice.MethodsMPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients who underwent biopsy was calculated across MPS quintiles and compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were performed in the overall referral population and the intended-use population (PSA 3-10 ng/ml or PSA ResultsOf 248 patients, 134 (54%) proceeded to prostate biopsy. Clinical variables, PSA, and PCPTrc score did not significantly differ based on the decision to undergo biopsy, while MPS was significantly higher in biopsied patients (median 29 vs. 14, pConclusionIn a cohort of patients who underwent clinical MPS testing as an alternative to immediate prostate biopsy, 46% were able to avoid biopsy and increasing MPS was strongly associated with biopsy rates. These findings were robust to the use of mpMRI and consistent across pertinent subpopulations. Overall, these data suggest that the MPS assay may substantially reduce the number of men undergoing prostate needle biopsy.
- Published
- 2020